Treatment of localized @entity9 of different etiologies with the 5% XXXX medicated plaster - a case series.

@entity1 @entity1931 @entity3303 @entity158 @entity282 @entity9
OBJECTIVE: To assess the efficacy and safety of the topical 5% @entity3303 medicated plaster in the treatment of localized @entity9 . STUDY DESIGN: This was a case series at an @entity158 clinic, using retrospective analysis. @entity1 AND METHODS: Data of 27 @entity1 treated for localized @entity9 with the 5% @entity3303 medicated plaster were retrospectively analyzed. Assessment included changes in overall @entity158 intensity, in intensity of different @entity158 qualities, and of @entity1931 and @entity1931 , and changes in sleep quality. RESULTS: @entity1 (17 female, ten male; mean age 53.4  11.4 years) presented mainly with dorsalgia (16 @entity1 ) or postoperative/posttraumatic @entity158 (seven @entity1 ); one @entity1 suffered from both. The mean overall @entity158 intensity prior to treatment with @entity3303 medicated plaster was 8.4  1.2 on the 11-point Likert scale. In the majority of cases, the @entity3303 plaster was applied concomitantly with preexisting @entity158 medication (81.5% of the @entity1 ). During the 6-month observation period, overall mean @entity158 intensity was reduced by almost 5 points (4.98) to 3.5  2.6. Substantial reductions were also observed for @entity158 (5 points from 7.9  2.6 at baseline) and @entity158 (3 points from 5.2  4.1). Sleep quality improved from 4.6  2.6 at baseline to 5.5  1.8. Stratification by @entity158 diagnosis showed marked improvements in overall @entity158 intensity for @entity1 with @entity282 . The @entity3303 plaster was well tolerated. CONCLUSION: Overall, topical treatment with the 5% @entity3303 medicated plaster was associated with effective @entity158 relief and was well tolerated.
